跳至主要内容
临床试验/ACTRN12619000054112
ACTRN12619000054112招募中4 期

A pharmacokinetic (PK) study of directly acting antiviral therapy for hepatitis C in pregnancy

Monash Health0 个研究点目标入组 10 人开始时间: 2019年1月15日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
Monash Health
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
Female

入选标准

  • Pregnant women mono-infected with hepatitis C, able to provide written, informed consent, will need to be able to provide contact details, have any HCV genotype with a detectable HCV RNA viral load at screening >1000 IU/ml, a gestational age of 22 weeks at enrollment and a singleton pregnancy with no known fetal anomalies (as confirmed on routine 18-22 week ultrasound).

排除标准

  • Women will be excluded from the study if they have previously had treatment for HCV with a NS5A inhibitor, use of any medications contraindicated with SOF/VEL, have a history of cirrhosis, have any significant uncontrolled active or chronic cardiovascular, renal, or liver disease, haematological, neurological, immunological or infectious disease (other than HCV), have a high risk of preterm birth (defined as a history of preterm birth at less than 34 weeks or a shortened cervical length of less than 20 millimeters).

研究者

发起方
Monash Health

相似试验